Skip to main content

Neuer Inhalt Free Registration

Gain full access to the latest clinical content available from Springer Nature

Editors' pick

06-16-2017 | Video

STAMPEDE trial changes standard of care

Nicholas James discusses the STAMPEDE trial results supporting use of abiraterone in advanced prostate cancer patients beginning long-term androgen deprivation therapy.

03-07-2017 | Brain metastases | Article

Comparing available criteria for measuring brain metastasis response to immunotherapy

Here we report a comparison between available response criteria when used to evaluate CNS response of patients from a Phase II trial studying the effect of pembrolizumab in patients with previously untreated or progressive melanoma or lung cancer brain metastases.

Qian JM et al. J Neurooncol 2017. doi:10.1007/s11060-017-2398-8

04-21-2017 | Lymphoma | Feature | Article

Lymphoma in practice: Professor Anas Younes speaks to medwireNews

Professor Anas Younes tells medwireNews about the current issues in lymphoma practice, both for the clinician and patients.

Latest from across the site

07-25-2017 | Epidemiology | News

Holocaust survivors at increased risk for cancer

Holocaust survivors have a small but significant increased risk for cancer, show findings of a study comparing individuals who were entitled to compensation for suffering persecution during the war with individuals denied such compensation.


Cancer 2017; Advance online publication

07-24-2017 | FDA | News


Extended neratinib adjuvant therapy approved for HER2-positive breast cancer

Click through to read more on this US FDA decision

07-21-2017 | Non-small cell lung cancer | News

News in brief

Hair repigmentation points to NSCLC immunotherapy response

Spanish researchers who observed hair repigmentation among patients with non-small-cell lung cancer who responded to immunotherapeutic drugs against programmed cell death protein 1 and its ligand believe that the side effect could serve as a potential marker of response.

07-20-2017 | Epidemiology | News

Rare cancer rates measured in Europe

Nearly a quarter of all cancers diagnosed in the European Union between 2000 and 2007 were classed as rare, according to updated epidemiologic information from the Information Network on Rare Cancers.


Lancet Oncol 2017; Advance online publication

07-19-2017 | Breast cancer | News

Genetic test identifies ultralow-risk breast cancers

The 70-gene MammaPrint assay can identify women who have an ultralow risk for death from breast cancer in the long term, potentially allowing their physicians to choose less aggressive treatment, say researchers.


JAMA Oncol 2017; Advance online publication

07-18-2017 | Prostate cancer | News

PIVOT: No survival benefit with surgery over observation in localized prostate cancer

All-cause and prostate cancer-specific mortality rates remain comparable over nearly 2 decades of follow-up among men with early prostate cancer regardless of whether they undergo radical prostatectomy or observation, the PIVOT trial shows.


N Engl J Med 2017; 377: 132–142

Meet our Advisory Board

image credits